Affimed (NASDAQ:AFMD) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Affimed (NASDAQ:AFMD) have received an average recommendation of “Moderate Buy” from the five analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $16.00.

A number of analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Affimed in a report on Friday, November 15th. Stifel Nicolaus dropped their target price on Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a report on Friday, November 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a research report on Tuesday, November 19th.

Affimed Price Performance

Shares of NASDAQ AFMD opened at $2.87 on Friday. The company’s fifty day moving average price is $3.36 and its 200 day moving average price is $4.41. Affimed has a 1 year low of $2.61 and a 1 year high of $8.95. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93.

Affimed (NASDAQ:AFMD) last announced its earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.09). Affimed had a negative net margin of 7,836.26% and a negative return on equity of 193.84%. The company had revenue of $0.17 million during the quarter, compared to analyst estimates of $1.67 million. Equities analysts forecast that Affimed will post -4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of AFMD. Point72 Asset Management L.P. raised its holdings in shares of Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after buying an additional 15,108 shares during the period. Jane Street Group LLC acquired a new stake in shares of Affimed during the third quarter worth about $44,000. Intellectus Partners LLC grew its holdings in shares of Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 10,250 shares in the last quarter. Choreo LLC acquired a new stake in shares of Affimed in the second quarter valued at $54,000. Finally, FMR LLC grew its stake in Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 4,086 shares in the last quarter. Institutional investors and hedge funds own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.